Hologic has signed a definitive agreement to acquire Gynesonics, a privately held medical device company focused on the development of minimally invasive solutions for women’s health, for approximately $350 million.

Gynesonics, which is based in Redwood City, California, develops and sells the Sonata System, the first FDA-cleared device for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The Sonata System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.

“Gynesonics’ Sonata System complements our offering and will give GYN surgeons across the globe an expanded range of options to treat women suffering from heavy periods and fibroids,” said Brandon Schnittker, division president of Surgical Solutions at Hologic. “This acquisition furthers our commitment to providing women with minimally invasive treatment options. We are enthusiastic about the future as we work to expand access to and drive innovation for treatments that enhance women’s quality of life.”

Earlier this year, Hologic entered an agreement to purchase Endomagnetics (Endomag) for about $310 million, a move intended to bolster the company's offerings in breast surgery by integrating advanced surgical guidance systems for breast cancer treatment.

Prior to that, Hologic and Bayer announced a contrast-enhanced mammography (CEM) collaboration, which will bring together Hologic's advanced mammography systems with Bayer's MEDRAD Stellant FLEX CT Injection System, which is notably the only CT injection system cleared by the FDA for CEM applications.

Completion of the acquisition is subject to customary closing conditions, including receipt of required regulatory approvals.